NasdaqGM:RLAYBiotechs
Relay Therapeutics (RLAY) Is Up 6.9% After Zovegalisib Phase 2 Data And Equity Raise - Has The Bull Case Changed?
Earlier in May 2026, Relay Therapeutics completed a US$275,000,004 follow-on equity offering at US$12 per share after releasing initial Phase 2 ReInspire data showing zovegalisib achieved a 60% volumetric response rate and broad symptom improvement in PIK3CA‑driven vascular anomalies with a safety profile supportive of chronic dosing.
An interesting angle is that zovegalisib is being advanced simultaneously in rare vascular anomalies and in an ongoing Phase 3 program for metastatic breast...
